Immunology in Lung Cancer: Biomarker Relevance and Integration of Therapies for Maximum Clinical Benefit
Friday, September 15, 2017
7:30 PM – 9:30 PM
Fairmont Chicago Millennium Park
200 N Columbus Drive
Chicago, IL 60601
Room: Gold Room
Naiyer A. Rizvi, MD (Chair)

Professor of Medicine
Director of Thoracic Oncology
Co-Director Cancer Immunotherapy Program
Columbia University Medical Center
New York, NY
David R. Gandara, MD
Professor, Director of Thoracic Oncology
Program, Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
Heather Wakelee, MD
Associate Professor of Medicine 
Department of Medicine 
Division of Medical Oncology
Stanford University Medical Center
Stanford, CA
This activity is provided by Paradigm Medical Communications, LLC.  

This meeting is being held in conjunction with IASLC 2017 Chicago.
Target Audience
This activity has been designed to address the educational needs of oncologists and multidisciplinary oncology care team practitioners. It will also be of benefit to other clinicians engaged with or interested in the treatment of lung cancer.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Describe concepts of cancer immunology as they relate to the mechanisms of action of immune checkpoint inhibitors.
  • Evaluate the latest evidence regarding the clinical utility and limitations of biomarkers in guiding treatment decisions and evaluating immunotherapy response in lung cancer.
  • Apply the latest efficacy and response pattern data for immune checkpoint inhibitors to the treatment of various types of lung cancer.
  • Outline strategies for the effective multidisciplinary management of immune-related adverse effects associated with immune checkpoint inhibition in lung cancer, including identification, treatment, and patient education.
7:30 PM – 8:00 PM          Registration and Complimentary Dinner Buffet
8:00 PM – 9:30 PM          Clinical Program
  • Introduction
    • Exploiting Cancer Immunology
    • Updates on Biomarkers for Immune Checkpoint Inhibitors
  • Integrating the Latest Efficacy Data into Clinical Practice
  • Collaborative Management of irAEs
  • Conclusions
  • Q&A
Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.5 Category 1 credits for completing this activity.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Inc and Merck & Co., Inc.
Disclosure of Conflicts of Interest
In accordance with ACCME requirements on disclosure, information about relationships with commercial interests (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.

To register for this complimentary symposium, please click Continue below or call toll-free: (877) 252-5100, ext. 1.